Maintaining Hold on Alkermes: Weighing Solid Performance …

Jul 25, 2024 · Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major ...

CouponFollow Extension

$25.00
OFF

Stifel Cuts Alkermes Stock Target, Hold Rating On Mixed Quarter …

1 week from now

On Thursday, Stifel, a financial services company, adjusted its outlook on shares of Alkermes (NASDAQ: NASDAQ: ALKS), reducing the price target to $25.00 from $28.00, while …

investing.com

$927
OFF

Alkermes Maintains Growth Trajectory Amid Financial Outlook

1 week from now

Oct 25, 2024 · The financial standing of Alkermes is robust, as the company concluded the quarter with $927.8 million in cash and investments. For the year ahead, expectations for net …

investorshangout.com

$380
OFF

Alkermes' OX2R Agonist For Narcolepsy Peaks Interest Amidst …

1 week from now

Nov 8, 2023 · To begin my analysis, looking at Alkermes' most recent earnings report, the company presented a strong financial performance with total revenues soaring to $380.9M for …

seekingalpha.com

$1.44
OFF

Alkermes: Fairly Valued After Post-Earnings Bump - Seeking Alpha

1 week from now

Jul 28, 2024 · Alkermes plc made $1.44 a share on $1.66 billion in revenue in FY2023. The current analyst firm consensus is for profits to surge to $2.70 a share in FY2024, even as …

seekingalpha.com

$355
OFF

Alkermes: Waking Up Narcolepsy Treatment With Promising Trial …

1 week from now

Apr 9, 2024 · Alkermes' net income for 2023 was $355 million. For 2024, Alkermes anticipates between $275 million and $295 million for Lybalvi. Total revenues are projected between $1.5 …

seekingalpha.com

5%
OFF

Why Alkermes (ALKS) Is A Top Momentum Stock For The Long-Term

1 week from now

Aug 16, 2024 · ALKS has a Momentum Style Score of A, and shares are up 9.5% over the past four weeks. Four analysts revised their earnings estimate higher in the last 60 days for fiscal …

nasdaq.com

$0.67
OFF

Alkermes Earnings: Here's What Wall Street Expects

1 week from now

Jul 23, 2024 · Alkermes will be reporting Q2 earnings on July 24.Analysts predict Alkermes will report earnings per share of $0.675.Go here to follow Alkermes st...

businessinsider.com

FAQs about Maintaining Hold on Alkermes: Weighing Solid Performance … Coupon?

Should you buy Alkermes (AlkS)?

Analyst Joseph Thome from TD Cowen maintained a Buy rating on Alkermes ( ALKS – Research Report) and increased the price target to $35.00 from $34.00. Joseph Thome has given his Buy rating due to a combination of factors including Alkermes’ solid second quarter performance and promising outlook on their pipeline products. ...

How did Alkermes plc perform in the second quarter?

Second Quarter Results: Alkermes plc posted its second quarter numbers on July 24th. The company posted non-GAAP earnings of 72 cents a share, a penny a share above the consensus. Revenues fell just over 35% on a year-over-year basis to $399.1 million. ...

What does Alkermes stand for?

Begin your TipRanks Premium journey today. Alkermes (ALKS) Company Description: Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. ...

Why has Uy ear rated Alkermes (Alkermes) a buy?

Uy Ear has given his Buy rating due to a combination of factors surrounding Alkermes’s recent financial performance and future potential. Alkermes’s second quarter of 2024 earnings surpassed expectations, which has alleviated investor concerns regarding the need to revise the company’s sales guidance for 2024. ...

How much money does Alkermes make a year?

Alkermes' net income for 2023 was $355 million. For 2024, Alkermes anticipates between $275 million and $295 million for Lybalvi. Total revenues are projected between $1.5 billion and $1.6 billion, with a net income of $350 million to $390 million. As of December 31, Alkermes has $457.4 million in cash and cash equivalents. ...

Is Alkermes stock underperforming the S&P 500?

Alkermes' stock momentum has been underperforming the S&P 500 in all timeframes. In the last year, ALKS is down 11% while the S&P is up 26%. Insider trading reveals positive activity over the past three (170,686 net activity) and twelve months (75,686). ...